Induced resistance to methionyl-tRNA synthetase inhibitors in Trypanosoma brucei is due to overexpression of the target

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3021-3028

  Ranade, Ranae M ^a   Gillespie, J Robert ^a   Shibata, Sayaka ^b   Verlinde, Christophe L M J ^b   Fan, Erkang ^b   Hol, Wim G J ^b   Buckner, Frederick S ^a  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITRYPANOSOMAL AGENT; EFLORNITHINE; MESSENGER RNA; METHIONINE TRANSFER RNA LIGASE; METHIONYL TRNA SYNTHETASE INHIBITOR; PENTAMIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIPROTOZOAL ACTIVITY; ARTICLE; GENE EXPRESSION; GENE MUTATION; IC 50; MALE; MOUSE; NONHUMAN; PARASITE VIRULENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOUTHERN BLOTTING; TRYPANOSOMA BRUCEI;

AMINOQUINOLINES; ANIMALS; BASE SEQUENCE; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; METHIONINE-TRNA LIGASE; MICE; PARASITIC SENSITIVITY TESTS; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

EID: 84879018716     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02578-12     Document Type: Article

References (29)

1. Brun R, Blum J, Chappuis F, Burri C. 2010. Human African trypanosomiasis. Lancet 375:148-159.
2. Simarro PP, Jannin J, Cattand P. 2008. Eliminating human African trypanosomiasis: where do we stand and what comes next? PLoS Med. 5:e55. doi:10.1371/journal.pmed.0050055. (Pubitemid 351317643)
3. Brun R, Don R, Jacobs RT, Wang MZ, Barrett MP. 2011. Development of novel drugs for human African trypanosomiasis. Future Microbiol. 6:677-691.
4. Giaever G, Chu AM, Ni L, Connelly C, Riles L, Véronneau S, Dow S, Lucau-Danila A, Anderson K, André B, Arkin AP, Astromoff A, El-Bakkoury M, Bangham R, Benito R, Brachat S, Campanaro S, Curtiss M, Davis K, Deutschbauer A, Entian KD, Flaherty P, Foury F, Garfinkel DJ, Gerstein M, Gotte D, Güldener U, Hegemann JH, Hempel S, Herman Z, Jaramillo DF, Kelly DE, Kelly SL, Kötter P, LaBonte D, Lamb DC, Lan N, Liang H, Liao H, Liu L, Luo C, Lussier M, Mao R, Menard P, Ooi SL, Revuelta JL, Roberts CJ, Rose M, Ross-Macdonald P, Scherens B, Schimmack G, Shafer B, Shoemaker DD, Sookhai-Mahadeo S, Storms RK, Strathern JN, Valle G, Voet M, Volckaert G, Wang CY, Ward TR, Wilhelmy J, Winzeler EA, Yang Y, Yen G, Youngman E, Yu K, Bussey H, Boeke JD, Snyder M, Philippsen P, Davis RW, Johnston M. 2002. Functional profiling of the Saccharomyces cerevisiae genome. Nature 418:387-391. (Pubitemid 34826834)
5. Charriere F, Helgadottir S, Horn EK, Soll D, Schneider A. 2006. Dual targeting of a single tRNA(Trp) requires two different tryptophanyl-tRNA synthetases in Trypanosoma brucei. Proc. Natl. Acad. Sci. U. S. A. 103:6847-6852.
6. Shibata S, Gillespie JR, Kelley AM, Napuli AJ, Zhang Z, Kovzun KV, Pefley RM, Lam J, Zucker FH, Van Voorhis WC, Merritt EA, Hol WG, Verlinde CL, Fan E, Buckner FS. 2011. Selective inhibitors of methionyltRNA synthetase have potent activity against Trypanosoma brucei infection in mice. Antimicrob. Agents Chemother. 55:1982-1989.
7. Charriere F, O'Donoghue P, Helgadottir S, Maréchal-Drouard L, Cristodero M, Horn EK, Söll D, Schneider A. 2009. Dual targeting of a tRNA ASP requires two different aspartyl-tRNA synthetases in Trypanosoma brucei. J. Biol. Chem. 284:16210-16217.
8. Duchene AM, Pujol C, Marechal-Drouard L. 2009. Import of tRNAs and aminoacyl-tRNA synthetases into mitochondria. Curr. Genet. 55:1-18.
9. Koh CY, Kim JE, Shibata S, Ranade RM, Yu M, Liu J, Gillespie JR, Buckner FS, Verlinde CL, Fan E, Hol WG. 2012. Distinct states of methionyl-tRNA synthetase indicate inhibitor binding by conformational selection. Structure 20:1681-1691.
10. Shibata S, Gillespie JR, Ranade RM, Koh CY, Kim JE, Laydbak JU, Zucker FH, Hol WG, Verlinde CL, Buckner FS, Fan E. 2012. Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: selectivity and in vivo characterization. J. Med. Chem. 55:6342-6351.
11. Wright GD, Poinar H. 2012. Antibiotic resistance is ancient: implications for drug discovery. Trends Microbiol. 20:157-159.
12. Matovu E, Geiser F, Schneider V, Mäser P, Enyaru JC, Kaminsky R, Gallati S, Seebeck T. 2001. Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy. Mol. Biochem. Parasitol. 117:73-81. (Pubitemid 32823484)
13. de Koning HP. 2008. Ever-increasing complexities of diamidine and arsenical crossresistance in African trypanosomes. Trends Parasitol. 24: 345-349.
14. Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q. 2000. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob. Agents Chemother. 44:2100-2108. (Pubitemid 30484433)
15. Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB. 1999. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am. J. Trop. Med. Hyg. 60:533-541. (Pubitemid 29233107)
16. Ojo KK, Gillespie JR, Riechers AJ, Napuli AJ, Verlinde CL, Buckner FS, Gelb MH, Domostoj MM, Wells SJ, Scheer A, Wells TN, Van Voorhis WC. 2008. Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob. Agents Chemother. 52:3710-3717.
17. Vincent IM, Creek D, Watson DG, Kamleh MA, Woods DJ, Wong PE, Burchmore RJ, Barrett MP. 2010. A molecular mechanism for eflornithine resistance in African trypanosomes. PLoS Pathog. 6:e1001204. doi: 10.1371/journal.ppat. 1001204.
18. Bridges DJ, Gould MK, Nerima B, Maser P, Burchmore RJ, De Koning HP. 2007. Loss of the high-affinity pentamidine transporter is responsible for high levels of cross-resistance between arsenical and diamidine drugs in African trypanosomes. Mol. Pharmacol. 71:1098-1108. (Pubitemid 46457013)
19. Barrett MP, Vincent IM, Burchmore RJ, Kazibwe AJ, Matovu E. 2011. Drug resistance in human African trypanosomiasis. Future Microbiol. 6:1037-1047.
20. Rubio MA, Ragone FL, Gaston KW, Ibba M, Alfonzo JD. 2006. C to U editing stimulates A to I editing in the anticodon loop of a cytoplasmic threonyl tRNA in Trypanosoma brucei. J. Biol. Chem. 281:115-120. (Pubitemid 43671169)
21. Jackson AP. 2007. Tandem gene arrays in Trypanosoma brucei: comparative phylogenomic analysis of duplicate sequence variation. BMC Evol. Biol. 7:54-62.
22. Arner E, Kindlund E, Nilsson D, Farzana F, Ferella M, Tammi MT, Andersson B. 2007. Database of Trypanosoma cruzi repeated genes: 20,000 additional gene variants. BMC Genomics 8:391-398.
23. Segovia M. 1994. Leishmania gene amplification: a mechanism of drug resistance. Ann. Trop. Med. Parasitol. 88:123-130. (Pubitemid 24201895)
24. Ouellette M, Borst P. 1991. Drug resistance and P-glycoprotein gene amplification in the protozoan parasite Leishmania. Res. Microbiol. 142: 737-746.
25. Jamnadass RH, Pelle R, Pandit P, Ricard B, Murphy NB. 2006. Trypanosoma brucei: composition, organisation, plasticity, and differential transcription of NlaIII repeat elements in drug-resistant and sensitive isolates. Exp. Parasitol. 113:244-255. (Pubitemid 44061789)
26. Ouellette M, Fase-Fowler F, Borst P. 1990. The amplified H circle of methotrexate-resistant Leishmania tarentolae contains a novel P-glycoprotein gene. EMBO J. 9:1027-1033.
27. Ouellette M, Papadopoulou B. 1993. Mechanisms of drug resistance in Leishmania. Parasitol. Today 9:150-153. (Pubitemid 23126424)
28. Sutcliffe JA. 2011. Antibiotics in development targeting protein synthesis. Ann. N. Y. Acad. Sci. 1241:122-152.
29. Hirumi H, Hirumi K. 1989. Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. J. Parasitol. 75:985-989. (Pubitemid 20099178)